Category Archives: Melanoma

Yervoy for Melanoma Treatment Reviewed by Leading Dermatologists

Yervoy (ipilumamab), a new medication for the treatment of melanoma, is reviewed by leading dermatologists Dr. Ramzi Saad and Dr. Richard Eisen.

“The breakthrough cancer medication from Bristol-Myers Squibb is Yervoy and it is specifically for patients with late-stage or metastatic melanoma. This is an exciting new weapon in the fight against skin cancer. We have two drugs out there that are used in the treatment of stage 3 and stage 4 melanoma – Interferon (which was approved a decade ago) and Dacarbazine. Yervoy is the first medication shown to prolong survival,” explained Dr. Saad.

Dr. Saad added that “ Yervoy is going to be a promising option for many. It prolongs life by six and a half months or more. The big issue is the significant side effect profile. But, Yervoy will undergo further rigorous testing to define it’s optimal use on melanoma patients.”

“Skin cancer is primarily caused by prolonged exposure to Ultraviolet A (UVA) and Ultraviolet B (UVB) rays from the sun or from tanning booths. UVA and UVB rays are present in tanning booths as well as on cloudy days and exposed skin is left vulnerable without sunblock or sunscreen. We’re all exposed to these rays every day, each time we go outdoors and the repeated exposure builds over time,” noted Dr. Richard Eisen, M.D.

According to South Shore Skin Center’s dermatologists, early skin cancer detection is imperative in the prevention and treatment of melanoma. If undetected and untreated, melanoma can quickly spread to the major organs and lymph nodes.

The dermatologists emphasize the need to follow key steps to prevent skin cancer including avoiding prolonged exposure to the sun, wearing protective clothing, and  applying sunscreen or sunblock with an SPF of 30 or higher every day even if it is cloudy.

They add that a person’s skin should be checked regularly by a dermatologist regularly, and any moles or other spots on the skin that have changed should be checked by physician as soon as possible.

Both Dr. Saad and Dr. Eisen practice provide medical care to patients at South Shore Skin Center in Cohasset, Massachusetts.

Melanoma Risk May be Reduced by Daily Sunscreen Use.

Regular use of sunscreen during a clinical trial of basal cell and squamous cell carcinomas was found to reduce the incidence of another type of skin cancer, melanoma, up to 10 years later, according to a new study published December 6, 2010 in an online edition of the Journal of Clinical Oncology.

The study showed that applying sunscreen every day to the head, neck, arms and hands reduced the chances of getting melanoma by half.

The study of 1,600 white adults randomized the participants into two groups 1) those that applied sunscreen every day and 2) those that applied sunscreen at their own discretion (prn).

During the 10-year follow-up period the researchers found that 11 people who used sunscreen daily were diagnosed with melanoma, compared to 22 people in the “discretionary use” group.

In addition, those that developed melanoma in the daily use” group were less likely to develop invasive melanoma, which is more difficult to effectively treat, than those in the “discretionary group”.

In a new story by Top News that covered the study, “Melanoma Risk ‘Lessens’ by Using Sunscreen“, Dr. Howard Kaufman, the Director of the Rush University Cancer Center in Chicago and a melanoma expert pointed out that “We have known for a long time that sunscreen prevents squamous and basal cell carcinomas but the data on melanoma has been a little bit confusing”.

This study strengthens the evidence showing that excessive UV exposure from the sun can increase the risk of developing melanoma, and that protecting oneself from those damaging UV rays can help to reduce that risk.

Melanoma Treatment with Immunotherapy Shows Potential

The American Society of Clinical Oncology will hold its annual meeting in Chicago this week where it will announce results of several studies investigating the use of immunotherapies for the treatment of melanoma.

Many of the immunotherapies used in the treatment of cancer are antibodies generated in a laboratory. These “monoclonal antibodies” bind to select portions of the immune system to alter the way the immune system responds to cancer cells.

Ipilimumab is one immunotherapy developed by Bristol-Myers Squibb (BMS) that has gained significant attention. Ipilimumab is a human monoclonal antibody that is undergoing clinical trials for the treatment of melanoma. Results from three small trials found that ipilimumab extended the life of stage IV melanoma patients.

(Tremelimumab another  monoclonal antibody produced by Pfizer was being investigated for the treatment of advanced melanoma, but a phase III trial was stopped in 2008 when interim data showed that results were not superior to standard chemotherapy)